Human cytomegalovirus (HCMV) replication is limited by HCMV-specific natural killer (NK) cell response. Distinct genetic polymorphisms, which are potentially involved in antiviral NK cell response, have been described. Here, the association between polymorphisms at IgG1 genetic marker 3/17, FcγRIIIα/ CD16a 158V/F, NKG2C wt/del , CD226/rs727088, and rs763361, respectively, and HCMV viremia and disease were investigated in 98 lung transplant recipients (LTRs), within 9 months after stop of posttransplant HCMV prophylaxis. From all variants, only the NKG2C wt/wt genotype was significantly associated with freedom from HCMV viremia (P = .0002) and disease (P = .02), compared with the NKG2C wt/del genotype. Thus, LTRs expressing the homozygous NKG2C wild type seem to have a selective advantage in HCMV defense.
Human cytomegalovirus (HCMV) may cause severe infections in lung transplant recipients (LTRs) and lead to increased morbidity and mortality [1] . Different innate and adaptive immune response mechanisms reduce HCMV replication even in the immunosuppressed host, and among these the natural killer (NK) cell response toward HCMV seems to play a particularly important role [2] . It was shown that especially adaptive NKG2C bright NK cells, which expand in response to HCMV infections [2] , can limit HCMV spread and reduce the severity of disease by robust antiviral effector functions, such as the secretion of cytokines and antibody (Ab)-dependent cellular cytotoxicity (ADCC) [3] . NKG2C bright cells can be activated either by interaction between the activating NK cell receptor NKG2C/ CD94 and its cellular ligand HLA-E or in an Ab-dependent pathway by interaction of the Fc part of immunoglobulin G (IgG) Abs with FcγR3a (CD16a) receptors [3] . In the last years, several genetic polymorphisms were identified at genes that are involved in NK cell activation pathways, and which therefore may influence the antiviral NK cell response. One of these polymorphisms was detected at the IGHG1 region of IgG1 Abs and causes the allelic genetic marker (GM; γ marker) variants 3 or 17. These variants occur in the white population, in about 52% (GM3/3), 39% (GM3/17), and 9% (GM17/17) of individuals, and were recently linked to Ab-effector functions including NK cell activation [4] . Another genetic polymorphism linked to the NK cell response is the heterozygous or homozygous deletion of the NKG2C gene, which was identified in 32.4% and 4% of the white population [5, 6] , respectively. Heterozygous deletion of NKG2C was linked to a decreased expression of the activating NKG2C receptor on the NK cell surface [5] , and presence of at least 1 deleted gene was associated with a trend toward symptomatic HCMV infection in kidney transplant recipients [6] . Furthermore, a single-nucleotide polymorphism (SNP) was described in the gene encoding the Fcγ receptor CD16a, which plays an important role in ADCC, and was shown to influence the affinity between IgG1 Abs and the FcγRIIIα/CD16a receptor on NK cells [7] . The CD16a 158V/V variant, present in about 11% of European populations, binds with higher affinity to IgG1 compared with the CD16a 158F/F variant, which occurs in 51% of European populations and thereby leads to an increased effector cell activity [7] . Also, DNAM-1/CD226 is an important protein for the activation of NK cells, mediating cellular adhesion to HCMV-infected cells and thus facilitating NK cell activation [8] . Two SNPs in the CD226 gene (rs727088 and rs763361) were recently described [9] .
The aim of the present study was to investigate whether any of these genetic variants or specific combinations thereof are associated with the development of HCMV viremia or disease in LTRs in posttransplantation follow-up. The patients' underlying diseases were chronic obstructive pulmonary disease (n = 54), cystic fibrosis (n = 29), pulmonary fibrosis (n = 25), and other (n = 25).
MATERIALS AND METHODS

Patients and Samples
All patients were followed up by quantitative HCMV polymerase chain reaction (PCR), weekly for 2 months, monthly to bimonthly for 1 year after transplantation and in larger intervals thereafter. When HCMV DNA levels of >1000 copies /mL plasma were detected, the patient was preemptively treated with (val-)ganciclovir. All patients were followed up for 9 months after stop of (val-)/ganciclovir prophylaxis. This was 1 year post-LTX in R + patients and 1 year and 9 months post-LTX in D + /R -patients. None of the patients experienced graft rejection, but 17 patients had HCMV disease, HCMV syndrome, or tissue invasive disease, as defined previously [1] , within the follow-up (HCMV pneumonia, n = 9; HCMV colitis, n = 4; HCMV hepatitis, n = 1; HCMV syndrome, n = 3).
HCMV PCR
HCMV DNA was isolated from plasma using a QIAamp RNA isolation kit (Qiagen, Hilden, Germany) and measured by Cobas Amplicor CMV Monitor Test Kit on a COBAS Amplicor Analyzer (both Roche Molecular Systems, Branchburg, New Jersey).
Genotyping
IgG1 GM3/17 heavy chain variants were determined by sequence analysis as described before [4] . The CD16a variants 158V/F and the SNPs at CD226, rs727088, and rs763361 were identified as previously described [10, 11] . NKG2C genotypes NKG2C wt/del were determined by touchdown PCR using HighFidelity PCR Master Mix (New England Biolabs, Ipswich, Massachusetts) as described previously [12] .
Statistical Analysis
The frequency distributions of D/R serostatus, gender, GM3/17, NKG2C wt/del , CD16a 158F/V, CD226 rs763361, and CD226 rs727088 between nonviremic patients, viremic patients, and patients with HCMV disease were calculated by 2 × 3 contingency tables using a χ 2 test. The age of the patients compared by Tukey test. Fisher exact test was performed to compare frequency distributions of the NKG2C. Odds ratio (OR), positive predictive value (PPV), and negative predictive value (NPV) were used to define a protective phenotype. Multivariate logistic regression analyses (with the D/R status as covariate) were used to identify combined genetic variables associated with the risk of viremia and HCMV disease. P values <.05 were considered significant. Statistical analyses were performed using GraphPad Prism (version 5.04) and IBM SPSS Statistics 24 software. The study was approved by the local ethics committee (EK number 1849/2017).
RESULTS
Patient Genotypes and HCMV Replication
Of the 98 patients transplanted between 2003 and 2011, 49 had no detectable HCMV viremia in the follow-up for 9 months after the stop of (val-)ganciclovir prophylaxis, 32 patients showed viremia of >1000 copies HCMV DNA/mL plasma without developing disease and received preemptive therapy, and 17 patients developed HCMV disease in the follow-up. All patients were tested for IgG1 GM3/17, NKG2C wt/del , CD16a 158V/F, and CD226 rs727088/rs763361 genotypes. The distribution of the individual genetic variants as well as of the patients' clinical and demographic data and their HCMV serostatus at transplantation are presented in Table 1 , as well as their distribution between the 3 patient groups (without viremia, with preemptively treated viremia, and with HCMV disease).
As shown in Table 1 , among the genetic polymorphisms, only the NKG2C wt/del polymorphism was significantly associated with the occurrence of HCMV viremia and HCMV disease after LTX (P = .000037, χ 2 test),whereas the IgG1 GM genotypes (P = .77, χ 2 test), CD16a 158VF variants (P = .6, χ 2 test), CD226 rs727088 (P = .39, χ 2 test), CD226 rs763361 (P = .74, χ 2 test) were not. Also, the impact of a combination of different genetic variants were assessed by multivariate logistic regression. The NKG2C variant alone was associated with the risk for viremia and disease (P = .00024) whereas neither another genetic marker nor a combination of variants significantly contributed to freedom from viremia and disease. Neither age at LTX (P = .3, Tukey test) nor gender (P = .83, χ 2 test) was associated with viremia or HCMV disease. However, D + /R -serostatus was associated with HCMV disease (P = .008, χ 2 test). Specific contingency table analysis between NKG2C variant and D/R status revealed no association between both factors (P = not significant, χ 2 test).
Specific Analysis of the NKG2C Deletion
The detailed analysis of the association between NKGC2 deletion genotypes and HCMV viremia or disease is presented in Figure 1A . The homozygous NKG2C del/del genotype only occurred in 2 patients, both with HCMV disease, and was therefore excluded from further statistical analyses. The NKG2C wt/wt genotype occurred significantly more frequently in nonviremic compared with viremic patients (P = .0002, Fisher exact test; OR, 6.5; PPV, 0.8; NPV, 0.63) and also compared with patients with HCMV disease (P = .02, Fisher exact test; OR, 4.5; PPV, 0.8; NPV, 0.53) than the NKG2C wt/del genotype. The NKG2C wt/del genotype was similarly distributed among viremic patients and viremic patients with HCMV disease (P = .75, Fisher exact test).
To confirm these findings, we further analyzed the association between the NKG2C variants and HCMV viremia and disease in 35 additional LTRs who were transplanted at a later time period and received an immunosuppressive induction scheme with Campath. The data are presented in Figure 1B . None of these 35 patients developed HCMV disease within 9 months after stop of (val-)ganciclovir prophylaxis. Also in this patient collective, the NKG2C wt/wt genotype was significantly more frequent in nonviremic compared with viremic patients (P = .0045, Fisher exact test; OR, 11.8; PPV, 0.68; NPV, 0.84). , and NKG2C del/del for each group. Fisher exact test was used for statistical comparison between the NKG2C wt/wt and NKG2C wt/del variants. *The NKG2C del/del variant was excluded from statistical evaluation because of its rare frequency (n = 2).
In the present study, we show that the heterozygous deletion of the NKG2C gene is significantly associated with the frequency of viremia and HCMV disease in LTRs within the first 9 months after stop of (val-)ganciclovir prophylaxis. So far, only limited data are available concerning the role of NKG2C variants in HCMV replication and disease in transplant recipients. Data exist from kidney transplant recipients, where it was shown that patients with the NKG2C wt/del genotype have a tendency to develop symptomatic HCMV infection [3] . In our patient cohort, the link between the heterozygous NKG2C deletion and HCMV viremia and disease is much more significant. Previous investigations have shown that a heterozygous deletion of the NKG2C gene goes along with a decreased absolute number of NKG2C + NK cells, with a decreased expression of NKG2C receptors on the NK cell surface and with a lower level of activation and degranulation of NKG2C + NK cells [13] . These impairments of the NK cell response may not be visible in the healthy host, but may lead to the enhanced replication of HCMV observed in our study in NKG2C wt/del patients, when other immunologic responses, in particular the T-cell response to HCMV, are severely depressed by the immunosuppressive therapy. We have analyzed also a group of patients who received induction with alemtuzumab, a CD52 inhibitor that causes a substantial depletion of different immune cells, also including NK cells to some degree [14] . The association between the NKG2C variants and HCMV viremia or disease posttransplantation were, however, found to be similar in patients with or without alemtuzumab treatment.
Also, in other viral infections, NKG2C deletion may play a significant role, and in HIV-infected patients the NKG2C deletion was associated with a faster progression and an increased susceptibility to HIV infection [15] .
The distribution of the NKG2C wt/del genotype found in our entire cohort was 40.6% and thus comparable to previous data [5] , showing a frequency of 32.4% for white populations. The NKG2C del/del is very rare; it was found only in about 4% of the white population [5] , and only in 2 (1.5%) of our study patients. Interestingly, both NKG2C del/del patients in our study cohort died from HCMV end-organ disease. This suggests that, in particular, LTRs with the rare homozygous NKG2C del/del variant may have difficulties in limiting HCMV replication and that the complete loss of the NKG2C gene may be linked to an especially poor outcome of HCMV infections under immunosuppression. More extended studies are required to confirm this.
None of the other genetic variants investigated in this study was linked significantly with HCMV viremia or disease within the first 9 months after stop of (val-)ganciclovir prophylaxis, either alone nor in combination with other genetic polymorphisms. The only other factor associated with HCMV viremia or disease was the patient's D/R serostatus. In agreement to what was described earlier, D + /R -patients developed significantly more frequently HCMV disease in the first months after stop of prophylaxis [1] . In our study cohort, the NKG2C variant and the D/R serostatus were, however, distributed independent from each other.
The present study is limited by the fact that the patients were followed up only for a 9-month period after stop of prophylaxis and, based on the present data, further studies with an extended follow-up would be important. In addition, further prospective investigations are necessary to assess the prognostic potential of the NKG2C wt/del genotype for the clinical follow-up. In conclusion, our data show that the NKG2C wt/del genotype is significantly associated with the development of HCMV viremia and disease in LTRs whereas the NKG2C wt/wt variant seems to predict a certain degree of freedom from HCMV replication. Further studies are needed to confirm whether the determination of the NKG2C gene variant may be useful to improve the HCMV management in patients after organ transplantation. 
